Related Experiment Videos
Advanced glycation in uraemic toxicity
1University of Louvain Medical School, Cliniques Universitaires St. Luc, Brussels, Belgium.
EDTNA/ERCA Journal (English Ed.)
|October 14, 2003
Summary
The Maillard reaction produces advanced glycation end products (AGEs) and reactive carbonyl compounds (RCOs), accelerating uraemic toxicity in diabetes and renal failure. Reducing AGEs and RCOs via dialysis or drugs may mitigate toxicity.
Area of Science:
- Biochemistry
- Nephrology
- Gerontology
Background:
- The Maillard reaction, a non-enzymatic process, forms advanced glycation end products (AGEs) from carbohydrates and proteins.
- This reaction accelerates in diabetes (hyperglycemia) and renal failure (reactive carbonyl compound accumulation), contributing to uraemic toxicity.
- AGEs and reactive carbonyl compounds (RCOs) are linked to clinical issues like dialysis amyloidosis, atherosclerosis, and altered peritoneal membrane permeability.
Purpose of the Study:
- To explore the role of AGEs and RCOs in uraemic toxicity.
- To identify therapeutic strategies for reducing AGEs and RCOs to mitigate uraemic toxicity.
Main Methods:
- Review of biochemical and clinical implications of AGEs and RCOs in uraemia.
- Analysis of therapeutic interventions including dialysis techniques and pharmacological agents.
Main Results:
- AGEs and RCOs are biochemical and clinical contributors to uraemic toxicity.
- Therapeutic strategies targeting AGEs and RCOs show promise in reducing uraemic toxicity.
Conclusions:
- Reducing plasma AGEs and RCOs is a potential therapeutic target for uraemic toxicity.
- Dialysis modifications and drugs inhibiting AGE formation are viable strategies to reduce uraemic toxicity.